← Back to patent-cliff list
Resiniferatoxin
Tier C — Watch / tradeResiniferatoxin
National Institute of Health, Islamabad
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：TRPV1
Indications (approved)：Osteoarthritis, 顽固性疼痛, 慢性膝关节痛, Knee arthritis, Morton神经瘤, Cancer pain, Pain, 间质性膀胱炎
Regional status
US
Phase III
2022-09-15
EU
Phase III
2022-08-26
China
-
Japan
Phase III
2022-08-26
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Resiniferatoxin?
Approved indications include: Osteoarthritis, 顽固性疼痛, 慢性膝关节痛, Knee arthritis, Morton神经瘤, Cancer pain, Pain, 间质性膀胱炎.
When does the Resiniferatoxin patent expire?
No public expiry year is available for Resiniferatoxin yet; this page updates once verified.
How do I get a quote for Resiniferatoxin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06